Skip to main content Accessibility help
×
Home
  • Print publication year: 2013
  • Online publication date: August 2013

12 - Contraception in the 30-somethings

Summary

In the area of contraception, especially combined oral contraceptives (COCs), ethinyl oestradiol (EE) has been the clear market leader for many decades. This chapter sets out the rather peculiar background to the inclusion of oestrogens in contraception as well as reviews some simple pharmacology. The classic mechanism of action for all steroid hormones is to bind to specific intracellular receptors and induce change in their shape, encouraging dimerization (two pairs of hormone/receptor complexes forming a single unit) and leading to recruitment of co-regulators. The complexes formed through this route are able to influence gene transcription and hence the production of proteins with biological activities. Until the last few years a prescriber discussing contraceptive options with a woman could bring in issues such as the route of administration of contraceptive steroids, their doses and dosing schedules and the type of progestogen.

References

1. Szarewski A. Sisters doing it for themselves. J Fam Plann Reprod Health Care 2009; 35(2): 71–2.
2. Szarewski A, von Stenglin A, Rybowski S. Women's attitudes towards monthly bleeding: results of a global population-based survey. Eur J Contracept Reprod Health Care 2012; 17(4): 270–83.
3. Kerns J, Darney P. Vaginal ring contraception. Contraception 2011; 83(2): 107–15.
4. Strowitzki T, Kirsch B, Elliesen J. Efficacy of ethinylestradiol 20 mg/drospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primary dysmenorrhoea: an open-label, multicentre, randomised, controlled study. J Fam Plann Reprod Health Care 2012; 38(2): 94–101.
5. Jensen JT, Garie SV, Trummer D, Elliesen J. Bleeding profile of a flexible extended regimen of ethinylestradiol/ drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study. Contraception 2012; 86(2): 110–18.
6. Klipping C, Duijkers I, Fortier MP, et al. Contraceptive efficacy and tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study. J Fam Plann Reprod Health Care 2012; 38: 73–83.
7. Klipping C, Duijkers I, Fortier MP, et al. Long-term tolerability of ethinylestradiol 20 mg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study. J Fam Plann Reprod Health Care 2012; 38: 84–93.
8. Mydr.com.au. How to take Yaz Flex. http://www.mydr.com.au/medicines/cmis/yaz-flex-tablets (accessed 3 March 2013).
9. Mansour D, Verhoeven C, Sommer W, et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17Î2-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinyloestradiol and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care 2011; 16: 430–43.
10. Mansour D. Safer prescribing of therapeutic norethisterone for women at risk of venous thromboembolism. J Fam Plann Reprod Health Care 2012; 38: 148–9.